Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 69

Fecal Microbiota Transplantation for Kidney Stone Patients

Official title: Fecal Microbiota Transplantation (FMT CAPSULE DE, FMPCapDE, MTP-CP101) in Kidney Stone Patients (FMT IND STUDY)

Run by Intermountain Health Care, Inc. · NCT05516472 · Data updated 2026-11-12

This study is testing if a new treatment using healthy gut bacteria can help people with recurring kidney stones caused by high levels of calcium and oxalate in their urine.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 69 Years
SexAll
Enrollment20 (estimated)
SponsorIntermountain Health Care, Inc.
Academic / other
Drugs / interventionsChemotherapy
Locations1 site (Park City, Utah)
StatusRecruiting
StartedOctober 10, 2024
Main results expectedDecember 2027
Study endsMarch 2028
Registry record updatedOctober 27, 2026
Trial IDNCT05516472 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 70 with a history of kidney stones composed of at least 50% calcium-oxalate and specific urinary parameters indicating hypercalciuria or hyperoxaluria.

Probably not a fit

Patients with metabolic syndrome or those currently participating in other interventional kidney stone studies may not benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of Microbial Transplant Therapy (MTT) on urinary parameters in patients with recurrent kidney stones, specifically those with hypercalciuria and hyperoxaluria. Participants will undergo screening and baseline assessments, including a 24-hour urine collection to analyze various urinary components. The study will enroll 36 patients divided into four groups based on their urinary stone composition, with some receiving MTT and others receiving a placebo. Stool samples will also be collected for metagenomic analysis prior to the intervention.

Why it matters

Potential benefit: If successful, this approach could provide a novel treatment option for patients suffering from recurrent kidney stones.

How similar studies have gone: While the use of microbial transplant therapy is a novel approach in this context, similar studies in other conditions have shown promising results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or older and younger than 70 years.
* Recent urinary stone disease with at least 50% calcium-oxalate composition confirmed by stone analysis.
* 24-hour urinary calcium \>225 mg/day or urinary oxalate \>40 mg/day.
* Able to provide informed consent.
* Willing to complete safety follow-up, study visits, 24-hour urine collections, and serial stool collections.
* Not actively participating in another interventional urinary stone disease trial.
* eGFR \>=60.

Exclusion Criteria:

* Three or more NIH-defined metabolic syndrome features.
* Any autoimmune disease or inflammatory bowel disease.
* Major gastrointestinal surgery within 3 months, excluding appendectomy or cholecystectomy; history of total colectomy or bariatric surgery.
* Primary or secondary hyperparathyroidism or PTH outside 15-65 pg/mL.
* Pancreatic enzyme replacement, ongoing dialysis, or eGFR \<60.
* Chemotherapy in the prior year or concurrent intensive cancer therapy.
* Antibiotics within 3 months of study entry, continued antibiotic need, or anticipated antibiotic use in the next 4 weeks.
* Unable to complete required washout from potassium citrate, thiazides, or proton pump inhibitors.
* Pregnant, breastfeeding, or planning pregnancy during the study.
* Unable or unwilling to swallow capsules, including CTCAE grade \>=2 dysphagia.
* Active gastrointestinal infection, toxic megacolon, or small bowel ileus.
* Life expectancy \<6 months.
* Prior FMT or microbiome-based product outside this study.
* Severe anaphylactic or anaphylactoid food allergy.
* Solid organ transplant recipient.
* Any condition jeopardizing safety or rights, preventing completion, or confounding results.
* Urinary oxalate \>=80 mg/day.

Where it's running

  • Park City Hospital
    Park City, Utah, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.